Literature DB >> 12359497

Opioid receptor genes inactivated in mice: the highlights.

C Gavériaux-Ruff1, B L Kieffer.   

Abstract

The opioid system controls nociception, stress responses, and addictive behaviors. Exogenous alkaloid opiates and endogenous opioid peptides stimulate mu-, delta- and kappa-opioid receptors, whose activities have long been analyzed by pharmacological tools. Mice lacking opioid receptor and opioid peptide precursor genes have now been produced by gene targeting. Behavioral analysis of mutant animals in the absence of drug has highlighted a distinct role of opioid receptors or peptides in nociception and revealed an important role for delta receptors in emotional behaviors. The examination of responses to drugs has clarified involvement of each receptor as molecular targets for exogenous opiates in vivo. Those data have also demonstrated the critical role of mu-receptor in cannabinoid and alcohol reinforcement and confirmed the involvement of kappa receptor in several dysphoric responses. Ongoing studies therefore help in understanding the molecular basis of opioid-controlled behaviors and will contribute to the development of novel therapeutics for pain, anxiety, and drug abuse.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359497     DOI: 10.1054/npep.2002.0900

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  42 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Advances in opioid pharmacology.

Authors:  Geoffrey K Gourlay
Journal:  Support Care Cancer       Date:  2004-12-21       Impact factor: 3.603

Review 3.  The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?

Authors:  Ji Hoon Yoo; Ian Kitchen; Alexis Bailey
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

4.  Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.

Authors:  Yunyun Yuan; Guo Li; Hengjun He; David L Stevens; Patrick Kozak; Krista L Scoggins; Pallabi Mitra; Phillip M Gerk; Dana E Selley; William L Dewey; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2011-05-06       Impact factor: 4.418

Review 5.  Panic, suffocation false alarms, separation anxiety and endogenous opioids.

Authors:  Maurice Preter; Donald F Klein
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-09       Impact factor: 5.067

6.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

Review 7.  The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.

Authors:  David Mysels; Maria A Sullivan
Journal:  Am J Addict       Date:  2009 Jul-Aug

Review 8.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

9.  Dual action of epidermal growth factor: extracellular signal-stimulated nuclear-cytoplasmic export and coordinated translation of selected messenger RNA.

Authors:  Nien-Pei Tsai; Ya-Lun Lin; Yao-Chen Tsui; Li-Na Wei
Journal:  J Cell Biol       Date:  2010-02-08       Impact factor: 10.539

10.  Delta receptors are required for full inhibitory coupling of mu-receptors to voltage-dependent Ca(2+) channels in dorsal root ganglion neurons.

Authors:  Wendy Walwyn; Scott John; Matthew Maga; Christopher J Evans; Tim G Hales
Journal:  Mol Pharmacol       Date:  2009-04-08       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.